Radiolabeled Tamoxifen Analogues for Imaging Breast Cancer with Spect
This study is aimed at developing SPECT ligands to image breast tumors. 99mTc-labeled tamoxifen (TX) analogue was prepared by reacting hydroxyethylthio TX analogue with reduced Tc-IV. The yield was 50–60% (purity >99%). 131I-TX was prepared by treating tosyl-TX with Na131I. The yield was 20–25% (>99% purity). Biodistribution studies of both analogues were performed in DMBA-induced mammary tumor-bearing rats (10 μCi/rat, i.v., n=3/timeinterval). Biodistribution 99mTc-TX at 1, 2, 4, 6 and 18 hrs showed a tumor uptake value (% injected dose/gram tissue) of 0.37±0.058, 0.38±0.066, 0.27±0.041, 0.28±0.124 and 0.10±0.013. Tumor/blood ratio ranged from 0.11 to 0.07. Tumor/muscle ratio ranged from 5.68 to 7.38. Biodistribution of 131I-TX at 1, 3, 6 and 24 hrs showed a tumor uptake value 0.18±0.062, 0.23±0.152, 0.26±0.166 and 0.27±0.016. When rats primed with estradiol (60 μg/rat, 3 days, s.c), the value changed to 0.30±0.033, 0.42± to 0.039, 0.48±0.107, and 0.40±0.123. Tumor/blood ratio ranged from 1.95 to 11.0. When rats pretreated with DES (1.2 mg/rat, iv), the tumor uptake value changed to 0.32±0.058 (99mTc-TX, 2 h) and 0.22±0.059 (131I-TX, 6 h). In rats pretreated with estradiol, a significant increase in tumor uptake value was observed after 131I-TX postinjection. 99mTc-TX uptake in tumor could not be blocked by DES, suggesting the uptake was not due to a receptor-mediated process. 131I-TX may be useful in differentiating functioning ER(+) breast tumors.
KeywordsEstrogen Receptor Tumor Uptake Biodistribution Study Gamma Scintigraphy Estrogen Receptor Assay
Unable to display preview. Download preview PDF.
- 3.M.E. McManaway, E.M. Jagoda, A. Kasid, W.C. Eckelman, B.E. Francis, S.M. Larson, R.E. Gibson, R.C. Reba and M.E. Lippman. [125I]17-beta-iodovinyl-11-beta-methoxyestradiol: in vivo and in vitro properties of a high affinity estrogen-receptor radiopharmaceutical. J. Nucl. Med. 25:472–477 (1984).Google Scholar
- 4.E.M. Jagoda, R.E. Gibson, H. Goodgold, N. Ferreira, B.E. Francis, R.C. Reba, W.J. Rzeszotarski and W.C. Eckelman. [125I]17-Iodovinyl-ll-beta-methoxyestradiol: in vivo and in vitro properties of a high affinity estrogen-receptor radiopharmaceutical. J. Nucl. Med. 25:472–477 (1984).PubMedGoogle Scholar
- 5.J.T. Hamm and J.C. Allegra. Hormonal therapy for cancer. In: Witts RE, ed. Manual of Oncologic Therapeutics. New York: Lippincott; 122–126 (1991).Google Scholar
- 6.J.L. Wittliff. Steroid-hormone receptor in breast cancer. Cancer Res. 53:630–643 (1984).Google Scholar
- 8.D. Yang and S. Wallace. High affinity tamoxifen derivatives and uses thereof. United States Patent Number 5,192,525, March 9, 1993.Google Scholar
- 9.D. Yang, S. Wallace, K.C. Wright, J.E. Price, L-R Kuang and E.E. Kim. Imaging of estrogen receptors with PET using 18F-fluoro analogue of tamoxifen. Radiology 185–186 (1992).Google Scholar
- 10.D.J. Yang, L-R Kuang, A. Cherif, W. Tansey, C. Li, W.J. Lin, C-W Liu, E.E. Kim and S. Wallace. Synthesis of 18F-alanine and 18F-tamoxifen for breast tumor imaging. J. Drug Targeting (1992) in press.Google Scholar
- 11.D.J. Yang, W.H. Wong, W. Tansey, K. Vargas, R. Tilbury, W. Broussard, L-R Kuang, S. Wallace and E.E. Kim. [18F]Fluoro analog of tamoxifen:radiosynthesis and imaging of estrogen receptors with PET. L Nucl. Med. 33(5), 985 (1992).Google Scholar
- 16.B.J. Fernandes, X.Y. Yao, D.J. Sutherland, S. Sidlofsky, M.E. Blackstein. DNA content and estrogen receptors in primary carcinoma of the breast. C.J.S. 34:349–355 (1991).Google Scholar